Transmission

Assay May Be Valuable for Screening Plasma Products

Published in Blood Weekly, March 30th, 2000

Aventis Behring, King of Prussia, Pennsylvania, presented to the U.S. Food and Drug Administration (FDA) Blood Products Advisory Committee information from its ongoing investigation into the use of proprietary polymerase chain reaction technology to screen for the presence of certain key viruses in plasma used in life-saving products.

The data indicate PCR screening may be valuable in identifying the presence of hepatitis B virus in plasma that has already cleared previous serology tests that screen for hepatitis B surface antigen, according to the company.

Investigational PCR screening, a form of nucleic acid testing (NAT), is designed to detect...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2000-03-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry